|
G |
TSLP |
thymic stromal lymphopoietin |
increases expression |
EXP |
(1->3)-beta-D-glucan increases expression of TSLP mRNA and protein in corneal epithelial cells |
RGD |
PMID:26874828 |
RGD:38549373 |
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
|
G |
ACAN |
aggrecan |
increases expression |
EXP |
alginic acid results in increased expression of ACAN mRNA |
CTD |
PMID:16371897 |
|
NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353
|
|
G |
ATG12 |
autophagy related 12 |
increases expression |
ISO |
Alginic Acid results in increased expression of ATG12 protein |
CTD |
PMID:35066102 |
|
NCBI chr 5:115,828,200...115,841,565
Ensembl chr 5:115,828,200...115,841,837
|
|
G |
ATG7 |
autophagy related 7 |
increases expression |
ISO |
Alginic Acid results in increased expression of ATG7 protein |
CTD |
PMID:35066102 |
|
NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression |
ISO |
Alginic Acid results in decreased expression of BCL2 protein |
CTD |
PMID:35066102 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of BCL2L1 protein |
CTD |
PMID:35066102 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BECN1 |
beclin 1 |
increases expression |
ISO |
Alginic Acid results in increased expression of BECN1 protein |
CTD |
PMID:35066102 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
CASP3 |
caspase 3 |
increases expression increases cleavage |
ISO |
Alginic Acid results in increased expression of CASP3 protein Alginic Acid results in increased cleavage of CASP3 protein |
CTD |
PMID:35066102 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
ISO |
Alginic Acid results in increased expression of and results in increased cleavage of CASP8 protein |
CTD |
PMID:35066102 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases expression |
ISO |
Alginic Acid results in increased expression of CASP9 protein |
CTD |
PMID:35066102 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
decreases expression |
ISO |
Alginic Acid results in decreased expression of CAT protein |
CTD |
PMID:35066102 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
COL10A1 |
collagen type X alpha 1 chain |
increases expression |
EXP |
alginic acid results in increased expression of COL10A1 mRNA |
CTD |
PMID:16371897 |
|
NCBI chr 6:116,118,909...116,217,144
Ensembl chr 6:116,118,909...116,158,747
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
increases expression |
ISO |
Alginic Acid results in increased expression of CYP17A1 protein |
CTD |
PMID:35066102 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of CYP19A1 protein |
CTD |
PMID:35066102 |
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
FSHR |
follicle stimulating hormone receptor |
decreases expression |
ISO |
Alginic Acid results in decreased expression of FSHR protein |
CTD |
PMID:35066102 |
|
NCBI chr 2:48,962,157...49,154,515
Ensembl chr 2:48,962,157...49,154,527
|
|
G |
GPX5 |
glutathione peroxidase 5 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of GPX5 protein |
CTD |
PMID:35066102 |
|
NCBI chr 6:28,525,881...28,534,955
Ensembl chr 6:28,525,881...28,534,955
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
alginic acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases lipidation |
ISO |
Alginic Acid results in increased lipidation of MAP1LC3B protein |
CTD |
PMID:35066102 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Alginic Acid results in increased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:35066102 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
RAB7A |
RAB7A, member RAS oncogene family |
increases expression |
ISO |
Alginic Acid results in increased expression of RAB7 protein |
CTD |
PMID:35066102 |
|
NCBI chr 3:128,726,183...128,814,798
Ensembl chr 3:128,693,669...128,825,942
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of SOD1 protein |
CTD |
PMID:35066102 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of SOD2 protein |
CTD |
PMID:35066102 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SQSTM1 |
sequestosome 1 |
decreases expression |
ISO |
Alginic Acid results in decreased expression of SQSTM1 protein |
CTD |
PMID:35066102 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
STAR |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
Alginic Acid results in decreased expression of STAR protein |
CTD |
PMID:35066102 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
alginic acid inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]; alginic acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; alginic acid inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of AKT1 protein] Chitosan results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:28732690 PMID:36706893 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
ALAD |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of ALAD protein] |
CTD |
PMID:22704994 |
|
NCBI chr 9:113,386,312...113,401,284
Ensembl chr 9:113,386,312...113,401,290
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
increases expression |
EXP |
Chitosan results in increased expression of ALPL mRNA; Chitosan results in increased expression of ALPL protein |
CTD |
PMID:25246786 |
|
NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410
|
|
G |
AOX1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in decreased expression of AOX1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 2:200,586,014...200,682,241
Ensembl chr 2:200,586,014...200,677,064
|
|
G |
ARB2A |
ARB2 cotranscriptional regulator A |
multiple interactions increases expression |
EXP |
ARB2A protein affects the reaction [Chitosan results in decreased expression of CPE protein]; ARB2A protein affects the reaction [Chitosan results in decreased expression of MMP9 protein]; ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK1 protein]; ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK3 protein] Chitosan results in increased expression of ARB2A mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 5:93,617,725...94,111,699
Ensembl chr 5:93,617,725...94,111,699
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in increased expression of BAX protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:18567086 PMID:30928397 PMID:38211767 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
[Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in decreased expression of BCL2 protein [Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of BCL2 protein]; [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:18567086 PMID:28732690 PMID:30928397 PMID:38211767 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
increases expression |
EXP |
Chitosan results in increased expression of BGLAP mRNA |
CTD |
PMID:25246786 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
CASP2 |
caspase 2 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP2 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
Chitosan metabolite inhibits the reaction [Copper results in increased activity of CASP3 protein] Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Chitosan inhibits the reaction [carbendazim results in increased expression of CASP3 protein]; Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP3 mRNA]] |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 PMID:38369055 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of CASP7 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein] |
CTD |
PMID:30928397 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
[Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; [Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Chitosan analog inhibits the reaction [ochratoxin A results in decreased activity of CAT protein]; Chitosan inhibits the reaction [carbendazim results in decreased expression of CAT protein]; Chitosan inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:12679053 PMID:22704994 PMID:27923682 PMID:30928397 PMID:35705592 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CLEC7A |
C-type lectin domain containing 7A |
multiple interactions decreases expression |
EXP |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC7A mRNA] Chitosan results in decreased expression of CLEC7A mRNA |
CTD |
PMID:21329777 |
|
NCBI chr12:10,116,777...10,130,304
Ensembl chr12:10,116,777...10,130,258
|
|
G |
COL15A1 |
collagen type XV alpha 1 chain |
decreases expression |
EXP |
Chitosan results in decreased expression of COL15A1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 9:98,943,907...99,070,787
Ensembl chr 9:98,943,179...99,070,787
|
|
G |
CPE |
carboxypeptidase E |
multiple interactions decreases expression |
EXP |
ARB2A protein affects the reaction [Chitosan results in decreased expression of CPE protein] Chitosan results in decreased expression of CPE mRNA; Chitosan results in decreased expression of CPE protein |
CTD |
PMID:36706893 |
|
NCBI chr 4:165,379,008...165,498,547
Ensembl chr 4:165,361,194...165,498,547
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of CTNNB1 protein] |
CTD |
PMID:28732690 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
multiple interactions |
ISO |
[Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:38211767 |
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases activity |
EXP |
Chitosan analog results in increased activity of CYP3A4 protein |
CTD |
PMID:20831879 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Fish Oils promotes the reaction [Chitosan inhibits the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]] |
CTD |
PMID:28987369 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
EXP |
Chitosan results in increased expression of DKK1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FOXO3 |
forkhead box O3 |
decreases phosphorylation |
EXP |
Chitosan results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:36706893 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
GCG |
glucagon |
increases expression increases secretion multiple interactions |
EXP |
Chitosan results in increased expression of GCG mRNA Chitosan results in increased secretion of GCG protein SB 203580 inhibits the reaction [Chitosan results in increased expression of GCG mRNA]; SB 203580 inhibits the reaction [Chitosan results in increased secretion of GCG protein] |
CTD |
PMID:23611362 |
|
NCBI chr 2:162,142,882...162,152,247
Ensembl chr 2:162,142,882...162,152,404
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased secretion of GOT1 protein] |
CTD |
PMID:35705592 |
|
NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased secretion of GPT protein] |
CTD |
PMID:35705592 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
[Chitosan analog co-treated with Quercetin] inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA]; [Chitosan analog co-treated with Quercetin] results in increased expression of GPX1 mRNA; Chitosan analog inhibits the reaction [ochratoxin A results in decreased expression of GPX1 mRNA] Chitosan analog results in increased expression of GPX1 mRNA |
CTD |
PMID:27923682 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in decreased expression of GSDMD mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 8:143,553,387...143,563,062
Ensembl chr 8:143,553,207...143,563,062
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of GSK3B protein] |
CTD |
PMID:28732690 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of GSR mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
EXP ISO |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 mRNA; [Chitosan metabolite results in decreased susceptibility to Copper] which results in increased expression of HMOX1 protein Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 mRNA]; Chitosan inhibits the reaction [carbendazim results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IL10 |
interleukin 10 |
multiple interactions increases secretion |
EXP |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Chitosan results in increased secretion of IL10 protein |
CTD |
PMID:21329777 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of IL1B mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
increases secretion multiple interactions |
EXP |
Chitosan results in increased secretion of IL6 protein Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21329777 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased expression of KEAP1 mRNA] |
CTD |
PMID:35705592 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation multiple interactions |
EXP |
Chitosan results in decreased phosphorylation of MAPK1 protein ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:36706893 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of MAPK3 protein] Chitosan results in decreased phosphorylation of MAPK3 protein ARB2A protein affects the reaction [Chitosan results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:28732690 PMID:36706893 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [Aminolevulinic Acid analog results in increased activity of MMP2 protein] |
CTD |
PMID:18806744 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
EXP |
Chitosan results in decreased expression of MMP9 mRNA; Chitosan results in decreased expression of MMP9 protein ARB2A protein affects the reaction [Chitosan results in decreased expression of MMP9 protein] |
CTD |
PMID:36706893 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
EXP ISO |
[Chitosan metabolite results in decreased susceptibility to Copper] which results in increased phosphorylation of NFE2L2 protein Chitosan analog affects the localization of NFE2L2 protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]; Chitosan inhibits the reaction [carbendazim results in decreased expression of NFE2L2 mRNA]; pyrazolanthrone inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; SB 203580 inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]] |
CTD |
PMID:25542178 PMID:30928397 PMID:35705592 PMID:38211767 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of NLRP3 mRNA]] |
CTD |
PMID:38369055 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Chitosan inhibits the reaction [carbendazim results in increased expression of NOS2 protein] |
CTD |
PMID:35705592 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of NQO1 mRNA] |
CTD |
PMID:30928397 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in increased expression of NR1H3 protein] |
CTD |
PMID:28987369 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
decreases phosphorylation |
EXP |
Chitosan results in decreased phosphorylation of PIK3CA protein |
CTD |
PMID:36706893 |
|
NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
decreases phosphorylation |
EXP |
Chitosan results in decreased phosphorylation of PIK3R1 protein |
CTD |
PMID:36706893 |
|
NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Chitosan co-treated with Fish Oils] inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein] |
CTD |
PMID:28987369 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
increases expression |
EXP |
Chitosan results in increased expression of PPARGC1A mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Cromolyn Sodium co-treated with Chitosan] inhibits the reaction [Dimethylhydrazines results in increased expression of RELA protein]; Chitosan promotes the reaction [Curcumin inhibits the reaction [fenpropathrin results in increased expression of RELA mRNA]] |
CTD |
PMID:28732690 PMID:38369055 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases expression |
EXP |
Chitosan results in increased expression of RUNX2 mRNA; Chitosan results in increased expression of RUNX2 protein |
CTD |
PMID:25246786 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SOD1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO |
Chitosan analog results in increased expression of SOD1 mRNA [Chitosan analog co-treated with Quercetin] results in increased expression of SOD1 mRNA; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of SOD1 mRNA] |
CTD |
PMID:27923682 PMID:30928397 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SPARCL1 |
SPARC like 1 |
decreases expression |
EXP |
Chitosan results in decreased expression of SPARCL1 mRNA |
CTD |
PMID:36706893 |
|
NCBI chr 4:87,473,335...87,529,376
Ensembl chr 4:87,473,335...87,531,061
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression |
EXP |
Chitosan results in increased expression of SPP1 mRNA |
CTD |
PMID:25246786 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Fish Oils co-treated with Chitosan] inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]; Chitosan inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:28987369 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of STAR mRNA] |
CTD |
PMID:38211767 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
TH |
tyrosine hydroxylase |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TH protein] |
CTD |
PMID:22704994 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
TLR2 |
toll like receptor 2 |
multiple interactions decreases expression |
EXP |
Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR2 mRNA] Chitosan results in decreased expression of TLR2 mRNA |
CTD |
PMID:21329777 |
|
NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,050...153,706,260
|
|
G |
TLR4 |
toll like receptor 4 |
decreases expression multiple interactions |
EXP |
Chitosan results in decreased expression of TLR4 mRNA Chitosan inhibits the reaction [Lipopolysaccharides results in decreased expression of TLR4 mRNA] |
CTD |
PMID:21329777 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases secretion |
EXP |
Chitosan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Chitosan results in increased secretion of TNF protein |
CTD |
PMID:21329777 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TPH1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased expression of TPH1 protein] |
CTD |
PMID:22704994 |
|
NCBI chr11:18,017,555...18,046,269
Ensembl chr11:18,017,555...18,046,269
|
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in increased expression of IL10 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IRAK1 |
interleukin 1 receptor associated kinase 1 |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:26576301 |
|
NCBI chr X:154,010,507...154,019,902
Ensembl chr X:154,010,506...154,019,902
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
[Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein] |
CTD |
PMID:30102254 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
SLC31A2 |
solute carrier family 31 member 2 |
decreases uptake |
ISO |
SLC31A2 protein results in decreased uptake of Dextrans |
CTD |
PMID:20930109 |
|
NCBI chr 9:113,151,007...113,164,140
Ensembl chr 9:113,150,976...113,164,140
|
|
G |
TNFRSF1B |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[Dextrans co-treated with ferrite analog] results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:26576301 |
|
NCBI chr 1:12,166,991...12,209,220
Ensembl chr 1:12,166,991...12,209,228
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC5 |
ATP binding cassette subfamily C member 5 |
increases export multiple interactions |
EXP |
ABCC5 protein results in increased export of Hyaluronic Acid [Curcumin analog binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [Curcumin binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [xanthohumol binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; Curcumin analog inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; Curcumin inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939
|
|
G |
ABRA |
actin binding Rho activating protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ABRA protein] |
CTD |
PMID:23178681 |
|
NCBI chr 8:106,759,483...106,770,244
Ensembl chr 8:106,759,483...106,770,244
|
|
G |
ACAN |
aggrecan |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of ACAN mRNA |
CTD |
PMID:23595953 |
|
NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353
|
|
G |
ACAT2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACAT2 protein] Hyaluronic Acid analog results in decreased expression of ACAT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:159,762,045...159,779,112
Ensembl chr 6:159,762,045...159,779,112
|
|
G |
ACO2 |
aconitase 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ACO2 protein |
CTD |
PMID:23178681 |
|
NCBI chr22:41,469,117...41,528,974
Ensembl chr22:41,447,830...41,529,273
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
ACTB |
actin beta |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of ACTB protein] Hyaluronic Acid analog affects the expression of ACTB protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
ACTC1 |
actin alpha cardiac muscle 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTC1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:34,790,230...34,795,549
Ensembl chr15:34,790,107...34,795,589
|
|
G |
ACTG2 |
actin gamma 2, smooth muscle |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTG2 protein] Hyaluronic Acid analog results in decreased expression of ACTG2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:73,893,008...73,919,865
Ensembl chr 2:73,892,314...73,919,865
|
|
G |
ACTR3 |
actin related protein 3 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ACTR3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
ALB |
albumin |
increases abundance |
EXP |
ALB protein results in increased abundance of Hyaluronic Acid |
CTD |
PMID:16642209 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
ANXA1 |
annexin A1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of ANXA1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,629
|
|
G |
ANXA2 |
annexin A2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:60,347,151...60,397,986
Ensembl chr15:60,347,134...60,402,883
|
|
G |
ANXA3 |
annexin A3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ANXA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:78,551,770...78,610,447
Ensembl chr 4:78,551,747...78,610,451
|
|
G |
ANXA4 |
annexin A4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
|
|
G |
ANXA5 |
annexin A5 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ANXA5 protein] Hyaluronic Acid analog results in decreased expression of ANXA5 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:121,667,946...121,696,980
Ensembl chr 4:121,667,946...121,696,995
|
|
G |
ARHGAP29 |
Rho GTPase activating protein 29 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of ARHGAP29 protein [Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of ARHGAP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:94,168,905...94,314,592
Ensembl chr 1:94,148,988...94,275,068
|
|
G |
ATG5 |
autophagy related 5 |
increases cleavage multiple interactions |
ISO |
Hyaluronic Acid results in increased cleavage of ATG5 protein roxadustat promotes the reaction [Hyaluronic Acid results in increased cleavage of ATG5 protein] |
CTD |
PMID:27082295 |
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
ATIC |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of ATIC protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATIC protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:215,312,059...215,368,592
Ensembl chr 2:215,311,956...215,349,773
|
|
G |
ATP5F1A |
ATP synthase F1 subunit alpha |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP5F1A protein] Hyaluronic Acid analog results in decreased expression of ATP5F1A protein |
CTD |
PMID:23178681 |
|
NCBI chr18:46,080,248...46,104,227
Ensembl chr18:46,080,248...46,104,334
|
|
G |
ATP5F1B |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ATP5F1B protein |
CTD |
PMID:23178681 |
|
NCBI chr12:56,638,175...56,645,984
Ensembl chr12:56,638,175...56,645,984
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid results in increased expression of BNIP3 protein roxadustat promotes the reaction [Hyaluronic Acid results in increased expression of BNIP3 protein] |
CTD |
PMID:27082295 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
CA3 |
carbonic anhydrase 3 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAR3 protein] Hyaluronic Acid analog results in decreased expression of CAR3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:85,438,859...85,449,040
Ensembl chr 8:85,373,436...85,449,040
|
|
G |
CALR |
calreticulin |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of CALR protein |
CTD |
PMID:23178681 |
|
NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489
|
|
G |
CALU |
calumenin |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of CALU protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CALU protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:128,739,359...128,773,400
Ensembl chr 7:128,739,292...128,773,400
|
|
G |
CAMK1 |
calcium/calmodulin dependent protein kinase I |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAMK1 protein] Hyaluronic Acid analog results in decreased expression of CAMK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:9,757,347...9,769,947
Ensembl chr 3:9,757,347...9,769,992
|
|
G |
CASP1 |
caspase 1 |
increases cleavage |
ISO |
Hyaluronic Acid results in increased cleavage of CASP1 protein |
CTD |
PMID:33383130 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP10 |
caspase 10 |
multiple interactions |
EXP |
[Diclofenac co-treated with Hyaluronic Acid] results in increased activity of CASP10 protein |
CTD |
PMID:20237495 |
|
NCBI chr 2:201,183,141...201,229,406
Ensembl chr 2:201,182,872...201,229,428
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] |
CTD |
PMID:17879260 PMID:19047049 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
EXP |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
[Diclofenac co-treated with Hyaluronic Acid] results in increased activity of CASP8 protein |
CTD |
PMID:20237495 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:23692848 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases secretion |
ISO |
Hyaluronic Acid analog results in increased secretion of CCL5 protein |
CTD |
PMID:9278343 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCT2 |
chaperonin containing TCP1 subunit 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT2 protein] Hyaluronic Acid analog results in decreased expression of CCT2 protein |
CTD |
PMID:23178681 |
|
NCBI chr12:69,585,459...69,601,570
Ensembl chr12:69,585,426...69,601,570
|
|
G |
CCT4 |
chaperonin containing TCP1 subunit 4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:61,868,085...61,888,671
Ensembl chr 2:61,868,085...61,888,671
|
|
G |
CCT5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCT5 protein] Hyaluronic Acid analog results in decreased expression of CCT5 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:10,249,921...10,266,412
Ensembl chr 5:10,249,929...10,266,389
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
multiple interactions increases expression affects binding |
EXP ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; Hyaluronic Acid analog binds to and results in increased activity of CD44 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of CD44 protein]; Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]; Verapamil inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]] Hyaluronic Acid metabolite results in increased expression of CD44 mRNA; Hyaluronic Acid metabolite results in increased expression of CD44 protein |
CTD |
PMID:9929743 PMID:12402308 PMID:19047049 PMID:20159036 PMID:23692848 PMID:31285260 More...
|
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CFL1 |
cofilin 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CFL1 protein] Hyaluronic Acid analog results in decreased expression of CFL1 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
multiple interactions |
EXP |
[Diclofenac co-treated with Hyaluronic Acid] results in decreased expression of CFLAR protein |
CTD |
PMID:20237495 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CFTR |
CF transmembrane conductance regulator |
increases export multiple interactions |
EXP |
CFTR protein results in increased export of Hyaluronic Acid Curcumin analog inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid]; xanthohumol inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
|
|
G |
CNN3 |
calponin 3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of CNN3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:94,896,957...94,927,110
Ensembl chr 1:94,896,949...94,927,223
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of COL2A1 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
COPS4 |
COP9 signalosome subunit 4 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of COPS4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:83,035,183...83,075,818
Ensembl chr 4:83,034,447...83,075,818
|
|
G |
COQ7 |
coenzyme Q7, hydroxylase |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] affects the expression of COQ7 protein Hyaluronic Acid analog results in increased expression of COQ7 protein |
CTD |
PMID:23178681 |
|
NCBI chr16:19,067,614...19,083,097
Ensembl chr16:19,067,614...19,080,095
|
|
G |
CPOX |
coproporphyrinogen oxidase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of CPOX protein] |
CTD |
PMID:23178681 |
|
NCBI chr 3:98,570,488...98,593,611
Ensembl chr 3:98,579,446...98,593,648
|
|
G |
CTH |
cystathionine gamma-lyase |
multiple interactions |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of CTH protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:70,411,268...70,439,851
Ensembl chr 1:70,411,218...70,439,851
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of CXCL8 protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of CXCL8 protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of CXCL8 protein |
CTD |
PMID:25053413 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
Hyaluronic Acid inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:30856093 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
DLD |
dihydrolipoamide dehydrogenase |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of DLD protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:107,891,107...107,921,198
Ensembl chr 7:107,891,162...107,931,730
|
|
G |
DNAJA1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of DNAJA1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:33,025,273...33,039,907
Ensembl chr 9:33,025,273...33,039,907
|
|
G |
DSTN |
destrin, actin depolymerizing factor |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of DSTN protein] Hyaluronic Acid analog results in decreased expression of DSTN protein |
CTD |
PMID:23178681 |
|
NCBI chr20:17,570,075...17,609,919
Ensembl chr20:17,570,075...17,609,919
|
|
G |
ECI2 |
enoyl-CoA delta isomerase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of ECI2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:4,115,706...4,135,575
Ensembl chr 6:4,115,693...4,135,597
|
|
G |
EEF1G |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF1G protein] |
CTD |
PMID:23178681 |
|
NCBI chr11:62,559,596...62,573,891
Ensembl chr11:62,559,596...62,574,086
|
|
G |
EEF2 |
eukaryotic translation elongation factor 2 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of EEF2 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EEF2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr19:3,976,056...3,985,463
Ensembl chr19:3,976,056...3,985,463
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF4E |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
EXP |
Hyaluronic Acid results in increased phosphorylation of EIF4E protein |
CTD |
PMID:16864594 |
|
NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133
|
|
G |
ENO1 |
enolase 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ENO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] |
CTD |
PMID:19047049 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,510...41,180,077
|
|
G |
ERP29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of ERP29 protein |
CTD |
PMID:23178681 |
|
NCBI chr12:112,013,426...112,023,449
Ensembl chr12:112,013,348...112,023,449
|
|
G |
ESD |
esterase D |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of ESD protein] |
CTD |
PMID:23178681 |
|
NCBI chr13:46,771,256...46,797,700
Ensembl chr13:46,771,256...46,797,420
|
|
G |
EZR |
ezrin |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of EZR protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:158,765,748...158,819,368
Ensembl chr 6:158,765,741...158,819,368
|
|
G |
FGF23 |
fibroblast growth factor 23 |
increases activity |
ISO |
Hyaluronic Acid analog results in increased activity of FGF23 protein |
CTD |
PMID:16081635 |
|
NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712
|
|
G |
FGF7 |
fibroblast growth factor 7 |
increases chemical synthesis |
ISO |
FGF7 protein results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:14506240 |
|
NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775
|
|
G |
FGG |
fibrinogen gamma chain |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of FGG protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of FGG protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:154,604,136...154,612,656
Ensembl chr 4:154,604,134...154,612,967
|
|
G |
FKBP4 |
FKBP prolyl isomerase 4 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of FKBP4 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FKBP4 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:2,794,970...2,805,423
Ensembl chr12:2,794,970...2,805,423
|
|
G |
FSCN1 |
fascin actin-bundling protein 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of FSCN1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of FSCN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:5,592,816...5,606,655
Ensembl chr 7:5,592,816...5,606,655
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions increases chemical synthesis |
EXP |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
FUBP1 |
far upstream element binding protein 1 |
multiple interactions affects expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of FUBP1 protein Hyaluronic Acid analog affects the expression of FUBP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:77,944,055...77,979,501
Ensembl chr 1:77,944,055...77,979,110
|
|
G |
GAB1 |
GRB2 associated binding protein 1 |
increases phosphorylation |
EXP |
Hyaluronic Acid results in increased phosphorylation of GAB1 protein |
CTD |
PMID:16864594 |
|
NCBI chr 4:143,336,876...143,474,565
Ensembl chr 4:143,336,876...143,474,565
|
|
G |
GDI1 |
GDP dissociation inhibitor 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GDI1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:154,437,154...154,443,467
Ensembl chr X:154,436,913...154,443,467
|
|
G |
GLRX3 |
glutaredoxin 3 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of GLRX3 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GLRX3 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:130,136,391...130,180,377
Ensembl chr10:130,136,391...130,184,521
|
|
G |
GNB1 |
G protein subunit beta 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:1,785,286...1,891,087
Ensembl chr 1:1,785,285...1,892,292
|
|
G |
GNB2 |
G protein subunit beta 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GNB2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:100,673,740...100,679,169
Ensembl chr 7:100,673,567...100,679,174
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of GOT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624
|
|
G |
GSDMD |
gasdermin D |
increases cleavage increases expression |
ISO |
Hyaluronic Acid results in increased cleavage of GSDMD protein Hyaluronic Acid results in increased expression of GSDMD mRNA |
CTD |
PMID:33383130 |
|
NCBI chr 8:143,553,387...143,563,062
Ensembl chr 8:143,553,207...143,563,062
|
|
G |
GSN |
gelsolin |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of GSN protein Hyaluronic Acid analog results in decreased expression of GSN protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:121,201,483...121,332,842
Ensembl chr 9:121,207,794...121,332,843
|
|
G |
GUCY2F |
guanylate cyclase 2F, retinal |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of GUCY2F protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:109,372,906...109,482,086
Ensembl chr X:109,372,906...109,482,086
|
|
G |
HAS1 |
hyaluronan synthase 1 |
increases expression |
EXP |
Hyaluronic Acid metabolite results in increased expression of HAS1 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS1 protein |
CTD |
PMID:31226360 |
|
NCBI chr19:51,713,112...51,723,991
Ensembl chr19:51,713,112...51,723,991
|
|
G |
HAS2 |
hyaluronan synthase 2 |
increases chemical synthesis affects abundance multiple interactions |
EXP ISO |
HAS2 protein results in increased chemical synthesis of Hyaluronic Acid HAS2 protein affects the abundance of Hyaluronic Acid [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid |
CTD |
PMID:11318944 PMID:31285260 |
|
NCBI chr 8:121,612,116...121,641,440
Ensembl chr 8:121,612,116...121,641,440
|
|
G |
HAS3 |
hyaluronan synthase 3 |
multiple interactions increases expression |
ISO EXP |
[HAS3 protein affects the susceptibility to Carbon Tetrachloride] which affects the abundance of Hyaluronic Acid; HAS3 protein affects the reaction [Carbon Tetrachloride results in increased abundance of Hyaluronic Acid] Hyaluronic Acid metabolite results in increased expression of HAS3 mRNA; Hyaluronic Acid metabolite results in increased expression of HAS3 protein |
CTD |
PMID:27042213 PMID:31226360 |
|
NCBI chr16:69,083,484...69,118,719
Ensembl chr16:69,105,653...69,118,719
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
Hyaluronic Acid results in increased expression of HIF1A protein roxadustat promotes the reaction [Hyaluronic Acid results in increased expression of HIF1A protein] |
CTD |
PMID:27082295 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HMBS |
hydroxymethylbilane synthase |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMBS protein] Hyaluronic Acid analog results in decreased expression of HMBS protein |
CTD |
PMID:23178681 |
|
NCBI chr11:119,084,881...119,093,549
Ensembl chr11:119,084,866...119,093,834
|
|
G |
HMMR |
hyaluronan mediated motility receptor |
multiple interactions |
EXP |
Hyaluronic Acid binds to and results in increased activity of HMMR protein |
CTD |
PMID:16864594 |
|
NCBI chr 5:163,460,632...163,491,941
Ensembl chr 5:163,460,203...163,491,941
|
|
G |
HNRNPA2B1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HNRNPA2B1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:26,189,927...26,200,746
Ensembl chr 7:26,171,151...26,201,529
|
|
G |
HNRNPH1 |
heterogeneous nuclear ribonucleoprotein H1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HNRNPH1 protein] Hyaluronic Acid analog results in decreased expression of HNRNPH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:179,614,178...179,634,784
Ensembl chr 5:179,614,178...179,634,784
|
|
G |
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HNRNPK protein |
CTD |
PMID:23178681 |
|
NCBI chr 9:83,968,083...83,980,615
Ensembl chr 9:83,968,083...83,980,631
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90AA1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of HSP90B1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSP90B1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:103,930,410...103,947,926
Ensembl chr12:103,930,107...103,953,931
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
affects expression multiple interactions |
ISO |
Hyaluronic Acid analog affects the expression of HSPA5 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of HSPA8 protein] Hyaluronic Acid analog results in decreased expression of HSPA8 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HSPB1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,305,813
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of HSPD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
IDH1 |
isocitrate dehydrogenase (NADP(+)) 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of IDH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:208,236,227...208,255,071
Ensembl chr 2:208,236,229...208,266,074
|
|
G |
IDH2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of IDH2 protein |
CTD |
PMID:23178681 |
|
NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477
|
|
G |
IDO1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of IDO1 protein] Hyaluronic Acid analog results in decreased expression of IDO1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
Hyaluronic Acid inhibits the reaction [Acetaminophen results in increased expression of IFNG protein] |
CTD |
PMID:18237725 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL12B |
interleukin 12B |
increases secretion |
ISO |
Hyaluronic Acid analog results in increased secretion of IL12B protein |
CTD |
PMID:9278343 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL1B |
interleukin 1 beta |
increases abundance increases expression multiple interactions |
EXP ISO |
IL1B protein results in increased abundance of Hyaluronic Acid Hyaluronic Acid results in increased expression of IL1B mRNA [Hyaluronic Acid co-treated with resveratrol] results in decreased expression of IL1B mRNA Hyaluronic Acid metabolite results in increased expression of IL1B mRNA; Hyaluronic Acid metabolite results in increased expression of IL1B protein [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL1B protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein; [IL1B protein results in increased expression of HAS2 protein] which results in increased chemical synthesis of Hyaluronic Acid; [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein]; Sulindac inhibits the reaction [IL1B protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:11318944 PMID:23595953 PMID:23692848 PMID:25053413 PMID:33383130 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
[acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of IL6 protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL6 protein |
CTD |
PMID:25053413 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IRAK3 |
interleukin 1 receptor associated kinase 3 |
increases expression |
EXP |
Hyaluronic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:15728517 |
|
NCBI chr12:66,189,214...66,254,622
Ensembl chr12:66,189,195...66,254,622
|
|
G |
ITIH1 |
inter-alpha-trypsin inhibitor heavy chain 1 |
multiple interactions |
EXP |
TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:25561734 |
|
NCBI chr 3:52,777,599...52,792,068
Ensembl chr 3:52,777,595...52,792,068
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation |
EXP |
Hyaluronic Acid analog results in increased phosphorylation of JUN protein |
CTD |
PMID:12402308 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KRT10 |
keratin 10 |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of KRT10 protein] Hyaluronic Acid analog results in increased expression of KRT10 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:40,818,117...40,822,614
Ensembl chr17:40,818,117...40,822,614
|
|
G |
LAP3 |
leucine aminopeptidase 3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of LAP3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:17,577,198...17,607,970
Ensembl chr 4:17,577,198...17,607,972
|
|
G |
LDHB |
lactate dehydrogenase B |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LDHB protein] |
CTD |
PMID:23178681 |
|
NCBI chr12:21,635,342...21,657,842
Ensembl chr12:21,635,342...21,757,857
|
|
G |
LGALS1 |
galectin 1 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in increased expression of LGALS1 protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide results in decreased expression of LGALS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr22:37,675,636...37,679,802
Ensembl chr22:37,675,636...37,679,802
|
|
G |
LMNA |
lamin A/C |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LMNA protein] Hyaluronic Acid analog results in increased expression of LMNA protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:156,082,573...156,140,081
Ensembl chr 1:156,082,572...156,140,081
|
|
G |
LRPAP1 |
LDL receptor related protein associated protein 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of LRPAP1 protein] Hyaluronic Acid analog results in decreased expression of LRPAP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:3,503,612...3,532,422
Ensembl chr 4:3,503,612...3,532,446
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions increases cleavage |
ISO |
roxadustat promotes the reaction [Hyaluronic Acid results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:27082295 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP2K1 |
mitogen-activated protein kinase kinase 1 |
increases phosphorylation |
EXP |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:12402308 |
|
NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656
|
|
G |
MAP2K2 |
mitogen-activated protein kinase kinase 2 |
increases phosphorylation |
EXP |
Hyaluronic Acid analog results in increased phosphorylation of MAP2K2 protein |
CTD |
PMID:12402308 |
|
NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122
|
|
G |
MAP3K1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog affects the localization of [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog promotes the reaction [MAP3K1 protein binds to CD44 protein]; Hyaluronic Acid analog results in increased phosphorylation of and results in increased activity of MAP3K1 protein |
CTD |
PMID:20159036 |
|
NCBI chr 5:56,815,549...56,896,152
Ensembl chr 5:56,815,549...56,896,152
|
|
G |
MAP3K3 |
mitogen-activated protein kinase kinase kinase 3 |
multiple interactions |
ISO |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr17:63,622,417...63,696,305
Ensembl chr17:63,622,415...63,696,305
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP ISO |
Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; U 0126 inhibits the reaction [Hyaluronic Acid analog results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12402308 PMID:20159036 PMID:20633555 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK7 |
mitogen-activated protein kinase 7 |
multiple interactions |
ISO |
MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr17:19,377,750...19,383,544
Ensembl chr17:19,377,721...19,383,544
|
|
G |
MFN1 |
mitofusin 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of MFN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:179,347,709...179,394,936
Ensembl chr 3:179,347,709...179,394,936
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with Resveratrol] results in decreased expression of MMP1 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160
|
|
G |
MMP13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP13 mRNA Hyaluronic Acid metabolite results in increased expression of MMP13 mRNA; Hyaluronic Acid metabolite results in increased expression of MMP13 protein |
CTD |
PMID:23595953 PMID:23692848 |
|
NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
affects activity |
ISO |
Hyaluronic Acid affects the activity of MMP2 protein |
CTD |
PMID:15597151 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in decreased expression of MMP3 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
affects activity |
ISO |
Hyaluronic Acid affects the activity of MMP9 protein |
CTD |
PMID:15597151 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein] |
CTD |
PMID:14697411 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MRPS7 |
mitochondrial ribosomal protein S7 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of MRPS7 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:75,261,879...75,266,376
Ensembl chr17:75,261,674...75,266,376
|
|
G |
MUS81 |
MUS81 structure-specific endonuclease subunit |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MUS81 protein] Hyaluronic Acid analog results in decreased expression of MUS81 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:65,859,674...65,867,653
Ensembl chr11:65,857,126...65,867,653
|
|
G |
MYL12A |
myosin light chain 12A |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12A protein] Hyaluronic Acid analog results in decreased expression of MYL12A protein |
CTD |
PMID:23178681 |
|
NCBI chr18:3,247,482...3,256,237
Ensembl chr18:3,247,481...3,256,236
|
|
G |
MYL12B |
myosin light chain 12B |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of MYL12B protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of MYL12B protein] |
CTD |
PMID:23178681 |
|
NCBI chr18:3,262,133...3,278,461
Ensembl chr18:3,261,479...3,278,461
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 PMID:23692848 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
EXP ISO |
[Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] Hyaluronic Acid results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:17879260 PMID:33383130 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
increases expression |
ISO |
Hyaluronic Acid results in increased expression of NLRP3 mRNA; Hyaluronic Acid results in increased expression of NLRP3 protein |
CTD |
PMID:33383130 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108
|
|
G |
NME1 |
NME/NM23 nucleoside diphosphate kinase 1 |
decreases expression multiple interactions |
ISO |
Hyaluronic Acid analog results in decreased expression of NME1 protein Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:51,153,559...51,162,168
Ensembl chr17:51,153,559...51,162,428
|
|
G |
NME2 |
NME/NM23 nucleoside diphosphate kinase 2 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NME2 protein] Hyaluronic Acid analog results in decreased expression of NME2 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:51,165,536...51,171,744
Ensembl chr17:51,165,435...51,171,744
|
|
G |
NOS2 |
nitric oxide synthase 2 |
affects expression increases expression |
ISO |
Hyaluronic Acid affects the expression of NOS2 mRNA Hyaluronic Acid metabolite results in increased expression of NOS2 mRNA; Hyaluronic Acid metabolite results in increased expression of NOS2 protein |
CTD |
PMID:15597151 PMID:23692848 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NR1D1 |
nuclear receptor subfamily 1 group D member 1 |
decreases expression |
EXP |
Hyaluronic Acid results in decreased expression of NR1D1 mRNA |
CTD |
PMID:17075855 |
|
NCBI chr17:40,092,793...40,100,589
Ensembl chr17:40,092,793...40,100,589
|
|
G |
NRXN1 |
neurexin 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of NRXN1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:49,918,503...51,032,132
Ensembl chr 2:49,918,503...51,225,575
|
|
G |
OPTN |
optineurin |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of OPTN protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:13,100,082...13,138,308
Ensembl chr10:13,099,449...13,138,308
|
|
G |
PDE4D |
phosphodiesterase 4D |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PDE4D protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:58,969,038...60,522,128
Ensembl chr 5:58,969,038...60,522,120
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PDIA3 protein |
CTD |
PMID:23178681 |
|
NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279
|
|
G |
PDIA6 |
protein disulfide isomerase family A member 6 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PDIA6 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 2:10,783,391...10,837,712
Ensembl chr 2:10,783,391...10,837,977
|
|
G |
PGAM1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGAM1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444
|
|
G |
PGK1 |
phosphoglycerate kinase 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PGK1 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:78,104,248...78,129,295
Ensembl chr X:77,910,739...78,129,295
|
|
G |
PGLS |
6-phosphogluconolactonase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PGLS protein] |
CTD |
PMID:23178681 |
|
NCBI chr19:17,511,649...17,521,288
Ensembl chr19:17,511,636...17,521,288
|
|
G |
PHB1 |
prohibitin 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:49,404,052...49,414,882
Ensembl chr17:49,404,049...49,414,905
|
|
G |
PHGDH |
phosphoglycerate dehydrogenase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PHGDH protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:119,711,934...119,744,215
Ensembl chr 1:119,648,411...119,744,218
|
|
G |
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
increases phosphorylation |
EXP |
Hyaluronic Acid results in increased phosphorylation of PIK3CA protein |
CTD |
PMID:16864594 |
|
NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093
|
|
G |
PITPNA |
phosphatidylinositol transfer protein alpha |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PITPNA protein] |
CTD |
PMID:23178681 |
|
NCBI chr17:1,517,718...1,562,792
Ensembl chr17:1,517,718...1,562,792
|
|
G |
PLAU |
plasminogen activator, urokinase |
multiple interactions |
EXP |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAU protein |
CTD |
PMID:12402308 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PLAUR |
plasminogen activator, urokinase receptor |
multiple interactions |
EXP |
[Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR mRNA; [Hyaluronic Acid analog binds to and results in increased activity of CD44 protein] which results in increased expression of PLAUR protein |
CTD |
PMID:12402308 |
|
NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547
|
|
G |
PLS3 |
plastin 3 |
multiple interactions increases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PLS3 protein Hyaluronic Acid analog results in increased expression of PLS3 protein |
CTD |
PMID:23178681 |
|
NCBI chr X:115,561,174...115,650,861
Ensembl chr X:115,561,174...115,650,861
|
|
G |
PPIA |
peptidylprolyl isomerase A |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of PPIA protein Hyaluronic Acid analog results in decreased expression of PPIA protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:44,796,681...44,803,117
Ensembl chr 7:44,796,680...44,824,564
|
|
G |
PPP1CA |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in increased expression of PPP1CA protein |
CTD |
PMID:23178681 |
|
NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183
|
|
G |
PRDX1 |
peroxiredoxin 1 |
affects expression |
ISO |
Hyaluronic Acid analog affects the expression of PRDX1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:45,511,051...45,522,890
Ensembl chr 1:45,510,914...45,542,732
|
|
G |
PRDX2 |
peroxiredoxin 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PRDX2 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:12,796,823...12,801,800
Ensembl chr19:12,796,820...12,801,800
|
|
G |
PRDX6 |
peroxiredoxin 6 |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PRDX6 protein] Hyaluronic Acid analog affects the expression of PRDX6 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:173,477,335...173,488,815
Ensembl chr 1:173,477,330...173,488,815
|
|
G |
PRPH |
peripherin |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PRPH protein |
CTD |
PMID:23178681 |
|
NCBI chr12:49,295,147...49,298,686
Ensembl chr12:49,295,147...49,298,686
|
|
G |
PSMB1 |
proteasome 20S subunit beta 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMB1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:170,535,120...170,553,307
Ensembl chr 6:170,535,120...170,553,307
|
|
G |
PSMC2 |
proteasome 26S subunit, ATPase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of PSMC2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 7:103,347,524...103,369,395
Ensembl chr 7:103,328,570...103,370,346
|
|
G |
PSMC4 |
proteasome 26S subunit, ATPase 4 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in increased expression of PSMC4 protein] Hyaluronic Acid analog results in decreased expression of PSMC4 protein |
CTD |
PMID:23178681 |
|
NCBI chr19:39,971,165...39,981,764
Ensembl chr19:39,971,165...39,981,764
|
|
G |
PSMC5 |
proteasome 26S subunit, ATPase 5 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of PSMC5 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:63,827,431...63,832,019
Ensembl chr17:63,827,152...63,832,026
|
|
G |
PTK2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of PTK2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
|
|
G |
RACK1 |
receptor for activated C kinase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RACK1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 5:181,236,897...181,243,906
Ensembl chr 5:181,236,897...181,248,096
|
|
G |
RAN |
RAN, member RAS oncogene family |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RAN protein] Hyaluronic Acid analog results in decreased expression of RAN protein |
CTD |
PMID:23178681 |
|
NCBI chr12:130,872,066...130,877,678
Ensembl chr12:130,872,037...130,877,678
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
EXP ISO |
[[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA; [[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein; [[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Doxorubicin]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in decreased susceptibility to Etoposide]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of ABCB1 protein]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 mRNA]; Resveratrol inhibits the reaction [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] Hyaluronic Acid results in increased phosphorylation of RELA protein Hyaluronic Acid metabolite results in increased phosphorylation of RELA protein Hyaluronic Acid metabolite results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:17879260 PMID:19047049 PMID:23692848 PMID:31226360 PMID:33383130 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RENBP |
renin binding protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RENBP protein] |
CTD |
PMID:23178681 |
|
NCBI chr X:153,935,269...153,944,643
Ensembl chr X:153,935,269...153,944,687
|
|
G |
ROCK1 |
Rho associated coiled-coil containing protein kinase 1 |
increases phosphorylation |
EXP |
Hyaluronic Acid results in increased phosphorylation of ROCK1 protein |
CTD |
PMID:16864594 |
|
NCBI chr18:20,946,906...21,111,813
Ensembl chr18:20,944,612...21,111,813
|
|
G |
RPS12 |
ribosomal protein S12 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of RPS12 protein] Hyaluronic Acid analog results in decreased expression of RPS12 protein |
CTD |
PMID:23178681 |
|
NCBI chr 6:132,814,569...132,817,564
Ensembl chr 6:132,814,569...132,817,564
|
|
G |
SCRN1 |
secernin 1 |
multiple interactions decreases expression |
ISO |
[Hyaluronic Acid analog co-treated with Hydrogen Peroxide] results in decreased expression of SCRN1 protein Hyaluronic Acid analog results in decreased expression of SCRN1 protein |
CTD |
PMID:23178681 |
|
NCBI chr 7:29,920,103...29,990,289
Ensembl chr 7:29,920,104...29,990,289
|
|
G |
SEPTIN11 |
septin 11 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SEPTIN11 protein] Hyaluronic Acid analog results in decreased expression of SEPTIN11 protein |
CTD |
PMID:23178681 |
|
NCBI chr 4:76,949,752...77,040,154
Ensembl chr 4:76,949,751...77,040,384
|
|
G |
SEPTIN2 |
septin 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SEPTIN2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:241,315,355...241,354,027
Ensembl chr 2:241,315,100...241,354,027
|
|
G |
SERPINH1 |
serpin family H member 1 |
multiple interactions affects expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SERPINH1 protein] Hyaluronic Acid analog affects the expression of SERPINH1 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:75,562,253...75,572,783
Ensembl chr11:75,562,056...75,572,783
|
|
G |
SLC25A11 |
solute carrier family 25 member 11 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SLC25A11 protein |
CTD |
PMID:23178681 |
|
NCBI chr17:4,937,130...4,940,046
Ensembl chr17:4,937,130...4,940,053
|
|
G |
SLMAP |
sarcolemma associated protein |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SLMAP protein |
CTD |
PMID:23178681 |
|
NCBI chr 3:57,756,309...57,930,013
Ensembl chr 3:57,755,450...57,930,003
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions |
EXP |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMAD3 |
SMAD family member 3 |
multiple interactions |
EXP |
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid] |
CTD |
PMID:21520325 |
|
NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173
|
|
G |
SNAI2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
Hyaluronic Acid analog results in increased expression of SNAI2 mRNA; Hyaluronic Acid analog results in increased expression of SNAI2 protein |
CTD |
PMID:20159036 |
|
NCBI chr 8:48,917,598...48,921,429
Ensembl chr 8:48,917,598...48,921,740
|
|
G |
SNCB |
synuclein beta |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SNCB protein |
CTD |
PMID:23178681 |
|
NCBI chr 5:176,620,082...176,630,534
Ensembl chr 5:176,620,082...176,630,556
|
|
G |
SOD1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of SOD1 protein |
CTD |
PMID:23178681 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD3 |
superoxide dismutase 3 |
affects binding multiple interactions |
ISO |
SOD3 protein binds to Hyaluronic Acid SOD3 protein inhibits the reaction [[Copper co-treated with Hydrogen Peroxide] results in increased degradation of Hyaluronic Acid] |
CTD |
PMID:18165226 |
|
NCBI chr 4:24,795,573...24,800,842
Ensembl chr 4:24,789,912...24,800,842
|
|
G |
SORD |
sorbitol dehydrogenase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of SORD protein] |
CTD |
PMID:23178681 |
|
NCBI chr15:45,023,195...45,077,185
Ensembl chr15:45,023,147...45,077,185
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[Hyaluronic Acid co-treated with resveratrol] results in increased expression of SOX9 mRNA |
CTD |
PMID:23595953 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of SRC protein] |
CTD |
PMID:23178681 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
STAM2 |
signal transducing adaptor molecule 2 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of STAM2 protein |
CTD |
PMID:23178681 |
|
NCBI chr 2:152,116,801...152,175,763
Ensembl chr 2:152,116,801...152,175,763
|
|
G |
STIP1 |
stress induced phosphoprotein 1 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of STIP1 protein] Hyaluronic Acid analog results in decreased expression of STIP1 protein |
CTD |
PMID:23178681 |
|
NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
|
|
G |
TCP1 |
t-complex 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TCP1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:159,778,498...159,789,602
Ensembl chr 6:159,778,498...159,789,703
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP |
[CD44 protein affects the abundance of Hyaluronic Acid] affects the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:31285260 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFB2 |
transforming growth factor beta 2 |
multiple interactions increases abundance |
ISO |
MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]; MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid] |
CTD |
PMID:20633555 |
|
NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619
|
|
G |
TLR2 |
toll like receptor 2 |
increases expression multiple interactions |
ISO |
Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR2 protein Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR2 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,050...153,706,260
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions increases expression increases abundance |
ISO EXP |
Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [Hyaluronic Acid metabolite results in increased expression of TLR4 protein] Hyaluronic Acid metabolite results in increased expression of TLR4 mRNA; Hyaluronic Acid metabolite results in increased expression of TLR4 protein TLR4 protein results in increased abundance of Hyaluronic Acid [Lipopolysaccharides results in decreased activity of TLR4 protein] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of IL1B protein] |
CTD |
PMID:23692848 PMID:25053413 PMID:31226360 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases abundance increases expression |
ISO EXP |
[Chondroitin Sulfates co-treated with Hyaluronic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] [acetic anhydride results in increased acetylation of Hyaluronic Acid metabolite] which results in increased secretion of TNF protein; [Butyrates results in increased acylation of Hyaluronic Acid metabolite] inhibits the reaction [[Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein]; [Hyaluronic Acid metabolite binds to Acetates] which results in increased secretion of TNF protein TNF mRNA results in increased abundance of Hyaluronic Acid Hyaluronic Acid metabolite results in increased expression of TNF mRNA; Hyaluronic Acid metabolite results in increased expression of TNF protein |
CTD |
PMID:14697411 PMID:23692848 PMID:25053413 PMID:25106431 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
affects binding multiple interactions |
EXP |
TNFAIP6 protein modified form binds to Hyaluronic Acid TNFAIP6 protein promotes the reaction [ITIH1 protein binds to Hyaluronic Acid] |
CTD |
PMID:12401803 PMID:25561734 |
|
NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046
|
|
G |
TPM2 |
tropomyosin 2 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM2 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:35,681,993...35,690,056
Ensembl chr 9:35,681,992...35,690,056
|
|
G |
TPM3 |
tropomyosin 3 |
multiple interactions decreases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TPM3 protein] Hyaluronic Acid analog results in decreased expression of TPM3 protein |
CTD |
PMID:23178681 |
|
NCBI chr 1:154,155,308...154,192,100
Ensembl chr 1:154,155,308...154,194,648
|
|
G |
TPT1 |
tumor protein, translationally-controlled 1 |
decreases expression |
ISO |
Hyaluronic Acid analog results in decreased expression of TPT1 protein |
CTD |
PMID:23178681 |
|
NCBI chr13:45,333,471...45,341,183
Ensembl chr13:45,333,471...45,341,284
|
|
G |
TUBB |
tubulin beta class I |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of TUBB5 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 6:30,720,352...30,725,422
Ensembl chr 6:30,717,435...30,725,538
|
|
G |
VCP |
valosin containing protein |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VCP protein] |
CTD |
PMID:23178681 |
|
NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,053,928...35,072,668
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Hyaluronic Acid promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein] |
CTD |
PMID:20067761 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VIM |
vimentin |
increases expression multiple interactions affects expression |
ISO |
Hyaluronic Acid analog results in increased expression of VIM protein Hyaluronic Acid analog affects the reaction [Hydrogen Peroxide affects the expression of VIM protein] Hyaluronic Acid analog affects the expression of VIM protein |
CTD |
PMID:20159036 PMID:23178681 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
VPS33A |
VPS33A core subunit of CORVET and HOPS complexes |
multiple interactions increases expression |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of VPS33A protein] Hyaluronic Acid analog results in increased expression of VPS33A protein |
CTD |
PMID:23178681 |
|
NCBI chr12:122,229,564...122,266,494
Ensembl chr12:122,229,564...122,266,502
|
|
G |
WDR1 |
WD repeat domain 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of WDR1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 4:10,074,339...10,116,799
Ensembl chr 4:10,068,089...10,116,972
|
|
G |
YARS1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
ISO |
Hyaluronic Acid analog inhibits the reaction [Hydrogen Peroxide results in decreased expression of YARS1 protein] |
CTD |
PMID:23178681 |
|
NCBI chr 1:32,775,239...32,817,358
Ensembl chr 1:32,775,237...32,818,031
|
|